Immune phenotypes predict survival in patients with glioblastoma multiforme

[1]  Yu Yao,et al.  Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas , 2016, Medicine.

[2]  P. Roche,et al.  Suppression of antigen presentation by IL-10. , 2015, Current opinion in immunology.

[3]  I. Hermans,et al.  Enhanced immunosuppression by therapy‐exposed glioblastoma multiforme tumor cells , 2015, International journal of cancer.

[4]  A. Buck,et al.  Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy? , 2015, PloS one.

[5]  M. Gilbert,et al.  Treating recurrent glioblastoma: an update. , 2015, CNS oncology.

[6]  A. von Deimling,et al.  Proximity ligation assay evaluates IDH1R132H presentation in gliomas. , 2015, The Journal of clinical investigation.

[7]  M. Beyer,et al.  Epigenetic and transcriptional control of Foxp3+ regulatory T cells. , 2015, Seminars in immunology.

[8]  M. Wei,et al.  Manipulating IL-10 signalling blockade for better immunotherapy. , 2015, Cellular immunology.

[9]  P. Wen,et al.  Glioma in 2014: Unravelling tumour heterogeneity—implications for therapy , 2015, Nature Reviews Clinical Oncology.

[10]  K. Urbańska,et al.  Glioblastoma multiforme – an overview , 2014, Contemporary oncology.

[11]  V. Chekhonin,et al.  Extracellular vesicles shed by glioma cells: pathogenic role and clinical value , 2014, Tumor Biology.

[12]  F. Saggioro,et al.  Fas, FasL, and cleaved caspases 8 and 3 in glioblastomas: a tissue microarray-based study. , 2014, Pathology, research and practice.

[13]  Roberto Würth,et al.  New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells , 2014, BioMed research international.

[14]  Geir Egil Eide,et al.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level , 2013, Journal of Neuroimmunology.

[15]  X. Qu,et al.  Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. , 2013, Neuro-oncology.

[16]  M. Weller,et al.  APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. , 2013, Anticancer research.

[17]  Hyung-Seok Kim,et al.  Immunological characterization of glioblastoma cells for immunotherapy. , 2013, Anticancer research.

[18]  Jingting Jiang,et al.  Cytokine-induced killer cells promote antitumor immunity , 2013, Journal of Translational Medicine.

[19]  G. Maira,et al.  The influence of surgery on recurrence pattern of glioblastoma , 2013, Clinical Neurology and Neurosurgery.

[20]  S. Negrini,et al.  CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes , 2013, Cancer Immunology, Immunotherapy.

[21]  J. Sampson,et al.  Regulatory T Cells Move in When Gliomas Say “I DO” , 2012, Clinical Cancer Research.

[22]  Ravi Sirdeshmukh,et al.  Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis , 2012, PloS one.

[23]  D. Hafler,et al.  Regulatory T cells in the central nervous system , 2012, Immunological reviews.

[24]  Xiaomei Li,et al.  CD4+CD25+CD127low/− T Cells: A More Specific Treg Population in Human Peripheral Blood , 2012, Inflammation.

[25]  Hamid Cheshmi.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[26]  D. English,et al.  Alcohol consumption and risk of glioblastoma; evidence from the Melbourne collaborative cohort study , 2011, International journal of cancer.

[27]  J. Connor,et al.  Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. , 2011, Cancer research.

[28]  S. Robson,et al.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. , 2011, Neoplasia.

[29]  L. Moretta,et al.  Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-γ on activation , 2010, Proceedings of the National Academy of Sciences.

[30]  A. Cagigi,et al.  Cytotoxic T-lymphocytes secrete soluble factors that induce caspase-mediated apoptosis in glioblastoma cell lines , 2010, Journal of Neuroimmunology.

[31]  T. Whiteside,et al.  Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. , 2009, Journal of immunological methods.

[32]  M. Introna,et al.  Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. , 2009, Experimental hematology.

[33]  W. Hall,et al.  Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy , 2007, Journal of Neuro-Oncology.

[34]  H. Dressman,et al.  Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T Cells in Patients with Malignant Glioma Reveals Differential Expression of the Immunologic Transcriptome Compared with T Cells from Healthy Volunteers , 2006, Clinical Cancer Research.

[35]  M. Lesniak,et al.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. , 2006, Journal of neurosurgery.

[36]  V. Tombolini,et al.  High-grade gliomas: results in patients treated with adjuvant radiotherapy alone and with adjuvant radio-chemotherapy. , 2006, Anticancer research.

[37]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[38]  D. Zagzag,et al.  Angiogenesis in Gliomas: Imaging and Experimental Therapeutics , 2005, Brain pathology.

[39]  L. Bisset,et al.  Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland , 2004, European journal of haematology.

[40]  L. Liau,et al.  Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. , 2004, Journal of neurosurgery.

[41]  D. Quaglino,et al.  Changes in the expression of surface receptors on lymphocyte subsets in the elderly: Quantitative flow cytometric analysis , 2001, American journal of hematology.

[42]  M. Chiga,et al.  A Pilot Study of Autologous Cancer Cell Vaccination and Cellular Immunotherapy Using Anti-CD3 Stimulated Lymphocytes in Patients with Recurrent Grade III/IV Astrocytoma , 2000, Journal of Neuro-Oncology.

[43]  J. Tonn,et al.  Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. , 1997, Anticancer research.

[44]  N. Flomenberg,et al.  Differential expression and regulation of the human CD8a and CD8 chains , 1990 .

[45]  D. Louis,et al.  Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? , 2013, Nature Reviews Clinical Oncology.

[46]  S. Sengupta,et al.  Mechanisms of immune evasion by gliomas. , 2012, Advances in experimental medicine and biology.

[47]  D. Vergani,et al.  Human CD4+CD25(high)CD127 (low/neg) regulatory T cells. , 2012, Methods in molecular biology.

[48]  A. Todo-Bom,et al.  Aging and asthma - changes in CD45RA, CD29 and CD95 T cells subsets. , 2012, Allergologia et immunopathologia.

[49]  M. Santos-Rosad,et al.  Aging and asthma — – Changes in CD 45 RA , CD 29 and CD 95 T cells subsets , 2011 .

[50]  W. Hall,et al.  Expression of MHC I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy , 2006, Journal of Neuro-Oncology.

[51]  L. Terry,et al.  Differential expression and regulation of the human CD8 alpha and CD8 beta chains. , 1990, Tissue antigens.